ArticleEuropean radiology2021
Prognostic value of myocardial extracellular volume fraction evaluation based on cardiac magnetic resonance T1 mapping with T1 long and short in hypertrophic cardiomyopathy.
Article in European radiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 69 citations in OpenAlex.
- Hypertrophic cardiomyopathy: state of the art on diagnosis and current therapeutic approach.Cardiovascular ultrasound · 2026Review
- Relationships Between Regional Left Ventricular Myocardial Strain and Tissue Characteristics in Hypertrophic Cardiomyopathy.Journal of cardiovascular development and disease · 2026Article
- Cardiovascular magnetic resonance for therapy monitoring in cardiomyopathies.European heart journal. Imaging methods and practice · 2026Review
- Myocardial Fibrosis in Hypertrophic Cardiomyopathy: Leveraging Quantitative Imaging and Artificial Intelligence for Precision Management.Reviews in cardiovascular medicine · 2026Review
- Myocardial transit time mapping by CMR: A novel potential parameter of microcirculatory dysfunction in hypertrophic cardiomyopathy with and without atrial fibrillation.European journal of radiology open · 2026Article
- Prognostic Value of Left Ventricular Kinetic Energy for Predicting Major Adverse Events in Hypertrophic Cardiomyopathy.JACC. Asia · 2026Article
- One- and two-year structural changes of mavacamten therapy in hypertrophic obstructive cardiomyopathy: a case report with serial comprehensive CMR demonstrating continuous reverse remodelling.European heart journal. Case reports · 2026Article
- The spatial ventricular gradient is a non-invasive, vectorcardiographic correlate of cardiac fibrosis.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2026Article
- Left ventricular deformation and tissue characteristics in hypertrophic cardiomyopathy patients with HFpEF: a CMR study.BMC medical imaging · 2025Article
- Multimodality Imaging in the Evaluation of Hypertrophic Cardiomyopathy.Heart failure clinics · 2025Review
- Extracellular Volume Fraction Analysis on Cardiac Computed Tomography Is Useful for Predicting the Prognosis of Hypertrophic Cardiomyopathy.Journal of cardiovascular development and disease · 2025Article
- Cardiac magnetic resonance left atrioventricular coupling index as a prognostic tool in hypertrophic cardiomyopathy.ESC heart failure · 2025Article
- Screening for Fabry disease in patients with hypertrophic cardiomyopathy using cardiac magnetic resonance imaging.European radiology · 2025Article
- Considerations for drug trials in hypertrophic cardiomyopathy.ESC heart failure · 2025Review
- Imaging myocardial scar in hypertrophic cardiomyopathy: advances in CMR and CT.Frontiers in cardiovascular medicine · 2025Review
- Scanner-generated native T1 mapping: a novel approach for assessing myocardial fibrosis in coronary heart disease.Frontiers in cardiovascular medicine · 2025Article
- Cardiac magnetic resonance research advances in myocardial fibrosis of hypertrophic cardiomyopathy.Frontiers in cardiovascular medicine · 2025Review
- Cardiovascular Computed Tomography and Magnetic Resonance Imaging Guideline of the Brazilian Society of Cardiology and the Brazilian College of Radiology - 2024.Arquivos brasileiros de cardiologia · 2024Article
- Austrian consensus statement on the diagnosis and management of hypertrophic cardiomyopathy.Wiener klinische Wochenschrift · 2024Article
- Clinical Applications of Cardiac Magnetic Resonance Parametric Mapping.Diagnostics (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
Abstract
objectiveTo investigate the prognostic significance of T1 mapping using T1 long and short in hypertrophic cardiomyopathy (HCM) patients.
methodsA total of 263 consecutive patients with HCM referred for cardiovascular magnetic resonance (CMR) imaging were enrolled in this study. The imaging protocol consisted of cine, late gadolinium enhancement (LGE), and T1 mapping with T1 long and short. All patients were followed up prospectively. Outcome events were divided into the primary and secondary endpoint events. Primary endpoint events included cardiac death, heart transplant, aborted sudden death, and cardiopulmonary resuscitation after syncope. The secondary endpoint event was defined as unplanned rehospitalization for heart failure.
resultThe average follow-up duration was 28.3 ± 12.1 (range: 1-78) months. In all, 17 patients (7.0%) experienced a primary endpoint including 13 cardiovascular deaths, three aborted sudden deaths, and one resuscitation after syncope, and 34 patients experienced a secondary endpoint. Patients with primary endpoints showed a trend towards more extensive LGE (p < 0.001), significantly higher ECV (p < 0.001), and native T1 (p = 0.028) than those without events. In multivariate Cox regression analysis, ECV was independently associated with primary and secondary endpoints (p < 0.001 and p = 0.047, respectively). For every 3% increase, ECV portended a 1.374-fold increase risk of a primary endpoint occurring (p < 0.001). In the Kaplan-Meier survival analysis, the incidence of primary and secondary endpoint events was significantly higher in HCM with increased ECV (p < 0.001 and p = 0.009, respectively).
conclusionIn patients with HCM, ECV is a strong imaging marker for predicting adverse outcome. KEY POINTS: • ECV is a potent imaging index which has a strong correlation with LVEF and LVEDVI and can evaluate myocardial tissue structure and function. • ECV and LGE can provide a prognostic value in patients with hypertrophic cardiomyopathy. • ECV has stronger predictive effectiveness than LGE; even in the subgroup with LGE, ECV shows independent predictive significance for adverse events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.